SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$3.83 USD
-0.40 (-9.46%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.90 +0.07 (1.83%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SOPH 3.83 -0.40(-9.46%)
Will SOPH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SOPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SOPH
SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes SOPHiA GENETICS (SOPH) a New Buy Stock
SOPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
Other News for SOPH
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
Sophia Genetics announces collaboration agreement with AstraZeneca